Descripción de la empresa
Evolent Health, Inc. operates as a provider of specialty care management services within the United States, focusing on oncology, cardiology, and musculoskeletal markets through its subsidiary. The company functions within the broader Healthcare sector, specifically under the Health Information Services industry, which signifies its role in managing health plan administration and delivering integrated value-based care platforms. At a significant scale, Evolent Health holds a market capitalization of $283.56M and generates annual revenue of $1.88B, supported by a workforce of 4,200 employees. These valuation and revenue figures indicate that while the entity possesses substantial operational scale in terms of revenue generation, its market cap reflects a valuation that is currently decoupled from its top-line performance, suggesting a market perception that prioritizes cash flow metrics over earnings multiples. The disparity between its $1.88B revenue and $283.56M market cap highlights a company structure where the market values future cash generation capabilities more heavily than current profitability or historical earnings. This positioning places the firm in a unique niche where administrative management services are delivered with a focus on specific medical specialties, creating a distinct profile within the competitive health services landscape.
Salud financiera
The financial profile of Evolent Health, Inc. is characterized by a revenue of $1.88B recorded over the trailing twelve months, a net income of -$579.4M, and an EBITDA of $88.22M. The substantial gap between the $1.88B revenue and the -$579.4M net income reveals a highly aggressive cost structure or significant non-operating expenses that are eroding bottom-line profitability despite strong top-line activity. However, the company maintains positive free cash flow of $98.41M, which provides essential financial flexibility to fund operations, repay debt, or invest in the business without relying on external equity financing. This positive cash generation is critical given the negative net income, demonstrating that the company's cash conversion cycle is efficient enough to cover operational outflows. The margin analysis shows a gross margin of 21.3%, an operating margin of -2.1%, and a profit margin of -28.5%; the low gross margin indicates intense competition or high cost of goods sold in service delivery, while the negative operating and profit margins confirm that operating expenses and other costs are exceeding revenue. Regarding liquidity and leverage, the company holds $151.86M in cash against $989.70M in debt, resulting in a debt-to-equity ratio of 238.37, which indicates a highly leveraged balance sheet reliant on equity or retained earnings to service obligations. Despite the high leverage, a current ratio of 1.31 suggests adequate short-term liquidity, as current assets exceed current liabilities by a comfortable margin. Furthermore, return metrics show a return on equity of -66.5% and a return on assets of -0.1%, revealing that management has yet to generate positive returns on the capital invested or employed, signaling a period of significant investment or restructuring rather than efficient capital deployment.
Evaluación de valoración
Valuation metrics for Evolent Health, Inc. present a complex picture with a P/E ratio (TTM) listed as N/A due to the negative earnings, while the forward P/E stands at 5.75. The absence of a trailing P/E combined with a forward P/E of 5.75 implies that the market is pricing the stock based on anticipated future earnings recovery rather than historical performance, expecting a significant trajectory shift in profitability. The price-to-book ratio is recorded at 0.68, which indicates that the market is valuing the company at a discount relative to its book value, suggesting a lack of market premium or a potential undervaluation if assets are undervalued on the books. Alternative valuation measures such as the price-to-sales ratio of 0.15 and an EV/EBITDA of 12.71 provide context that the stock is trading at a fraction of its sales, which is typical for high-growth or turnaround firms but signals caution regarding current revenue quality. In terms of price volatility, the stock has traded between a 52-week high of $12.06 and a 52-week low of $2.10. Assuming a current trading context relative to these bounds, the price sits at a level that requires analysis of the percentage distance from the high to understand the extent of the recent correction or accumulation zone. The beta value of 0.37 indicates that the stock exhibits low volatility relative to the broader market, moving significantly less than the S&P 500 in both up and down markets, which offers a defensive characteristic for a highly leveraged healthcare entity.
Growth & Income
The growth profile is defined by a revenue growth (YoY) of -27.5% and an earnings growth (YoY) listed as N/A due to the negative earnings base. The contraction in revenue suggests a challenging operating environment or loss of business, and since earnings are negative, the comparison of earnings growth to revenue is not mathematically applicable in traditional terms, but the revenue decline implies a slowdown in the core business model. Regarding income, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This 0.0% payout ratio confirms that the company retains all available cash, reinvesting it into operations or debt reduction rather than distributing income to shareholders, which is a common strategy for firms with negative net income. Consequently, the overall growth and income profile reflects a company in a contractionary phase with no current income distribution, relying entirely on operational recovery and cash flow generation to drive future value creation.